FibroBiologics, Inc. (FBLG) intrinsic value & 10-year financials
FibroBiologics, Inc. (FBLG) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.97
- Market cap
- $43.4M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 219.9%
- Free cash flow (FY2025)
- -$16.7M
FBLG 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$18.6M | -$0.42 | -$16.7M | — | 456.1% |
| FY2024 | — | -$11.2M | -$0.34 | -$12.1M | — | 163.6% |
| FY2023 | — | -$16.5M | -$0.68 | -$6.9M | — | 161.0% |
| FY2022 | — | -$5.1M | -$0.18 | — | — | 98.9% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
FibroBiologics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
FibroBiologics, Inc. has earned high returns on invested capital, averaging 26.7% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
FibroBiologics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
FibroBiologics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.